NASDAQ · GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$150.93▲ 0.83% ($1.24)at close
After hours$151.69▲ 0.50%7:32 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 26.5% revenue growth a year for 10 years. Our scenarios assume 2.2–4.4%.
That's 13.9× its past 4-year pace.
Value per share
Base case
$6.23
Price used $150.93 is 24.2× this
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
Revenue each value needs
Revenue today $30.5B. The price needs $319B by 2036. Base case: $41.3B. At its recent pace: $36.8B. Bear to Bull: $37.9B to $46.9B.
Revenue today $30.5B. The price needs $319B by 2036. Base case: $41.3B. At its recent pace: $36.8B. Bear to Bull: $37.9B to $46.9B.
Revenue in 2036
today $30.5B
+$278Bmore than the Base case · 7.7×
Value per share · Base case
$6.23
Price $150.93
24.2× this
- 10-yr revenue CAGR
- 3.1%
- Ending operating margin
- 0.0%
- Discount rate
- 7.4%
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 35.99% over the last year. Revenue grew 5.52% over the trailing twelve months. Operating margin moved from 27.89% to -4.9%. Free cash flow grew 40.88% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/FCF range (88th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -4.9% — continued expansion would be needed to justify the premium. Revenue growth of 5.52% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Return analysis
Company profile
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets.
Market multiples
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
39
Buy
18
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 29, 2026
Q4 FY26 · EPS est $2.12 · Revenue est $7.77B
View
Institutional Sentiment
Gilead Sciences, Inc. · GILD
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.